Developing cancer immunotherapies

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue SUPPL. 1, 2011, Pages 9-13

  Davis, Ian D ^a   Cebon, Jonathan S ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Antigen; Cancer; Immunotherapy; NY ESO 1; Tumor; Tumor immunity

Indexed keywords

ADJUVANT; CANCER VACCINE; ISCOMATRIX; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

EID: 79953042844     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01382.x     Document Type: Review

References (22)

1. Cebon J, Gedye C, John T etal. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007; 5: 994-1006.
2. Davis ID, Jefford M, Parente P etal. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73: 3-29.
3. Nicholaou T, Ebert L, Davis ID etal. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006; 84: 303-17.
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
5. Kaufman HL, Disis ML. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 2004; 113: 664-7.
6. Marincola FM, Wang E, Herlyn M etal. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003; 24: 335-42.
7. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61: 65-73.
8. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
9. Wolf AM, Wolf D, Steurer M etal. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-12.
10. Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003; 26: 85-93.
11. Nicholaou T, Ebert LM, Davis ID etal. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009; 15: 2166-73.
12. Boon T, Coulie PG, Van den Eynde BJ etal. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
13. Schwartzentruber DJ, Lawson D, Richards J etal. A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009; 27 (Suppl. 18): abstract CRA9011.
14. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997; 16: 313-39.
15. Simpson AJ, Caballero OL, Jungbluth A etal. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
16. Hofmann O, Caballero OL, Stevenson BJ etal. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008; 105: 20422-7.
17. Cebon J. Cancer vaccines: where are we going? Asia Pac J Clin Oncol 2010; 6 (Suppl. 1): S9-15.
18. Yang B, O'Herrin SM, Wu J etal. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007; 67: 9954-62.
19. Barrow C, Browning J, MacGregor D etal. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12: 764-71.
20. Cebon JS, Svobodova S, Browning J etal. Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. J Clin Oncol 2009; 27 (Suppl. 15): abstract 9004.
21. Jackson H, Dimopoulos N, Mifsud NA etal. Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J Immunol 2006; 176: 5908-17.
22. Davis ID, Chen W, Jackson H etal. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101: 10697-702.